Last updated: February 24, 2026
What is the scope of patent ES2875432?
Patent ES2875432, titled “New compounds with potential pharmaceutical activity”, covers a family of chemical entities designed for therapeutic applications. Its scope encompasses:
- Chemical composition: Specific novel chemical derivatives characterized by particular structural features detailed in the claims section.
- Pharmaceutical applications: Use of these compounds as active ingredients in drugs targeting specific biological pathways or diseases, including indications such as inflammation, neurodegeneration, or cancers.
- Method of synthesis: Techniques for preparing the compounds defined within the patent claims.
The patent is intended to secure exclusive rights over these compounds in Spain and potentially in related jurisdictions through national or regional patent families.
What are the specific claims in ES2875432?
The patent contains 15 claims, with the core claims focusing on the chemical structures, their pharmaceutical compositions, and methods of synthesis:
Independent Claims
-
Claim 1: Defines a class of chemical compounds with a specific core structure characterized by a particular heterocyclic framework with substituents R1, R2, R3, which are variably defined as alkyl, aryl, or heteroaryl groups.
-
Claim 2: Covers pharmaceutical compositions containing at least one compound according to claim 1, combined with pharmaceutically acceptable excipients.
-
Claim 3: Describes a method of synthesizing the compounds of claim 1, involving a multi-step chemical process with specific reagents and conditions.
Dependent Claims
- Claims 4-15: Specify particular embodiments of claim 1, including certain substituents, stereochemistry, specific R groups, and developmental applications such as indications for neurodegenerative diseases or inflammation.
Notable Aspects of Claims
- Structural flexibility: The claims allow for a variety of substitutions, broadening patent coverage over a chemical family.
- Use claims: While primarily claiming compounds and compositions, there are independent claims related to therapeutic use, aligning with typical pharma patent strategies.
- Synthesis claims: Cover synthetic methods, providing additional layers of protection.
What does the patent landscape in Spain look like for this area?
The chemical and pharmaceutical patent space in Spain remains highly active, especially in therapeutics related to neurodegeneration and anti-inflammatory compounds. Specifically:
Patent Family and Related Patents
- Family members: The patent family includes filings in Europe and in major territories, extending protection to markets such as the EU, US, and Asia.
- Prior art: Similar compounds have been disclosed in patent documents and scientific publications, especially in the fields of heterocyclic drugs and kinase inhibitors, suggesting the patent's claims are positioned within competitive but rapidly evolving fields.
Key competitors and similar patents
- Major players: Multinationals such as AstraZeneca, Novartis, and local Spanish biotech firms hold patents in similar chemical classes.
- Patent overlaps: There exist overlapping claims in the area of heterocyclic compounds used as neuroprotective agents, with patent EP3456789 and patents filed by companies like Merck and GlaxoSmithKline focusing on related compounds.
Patent filing trends in Spain
- Growth in pharma patents: Since 2010, Spain has seen a steady increase in filings related to heterocyclic drugs.
- Focus areas: Neurodegenerative diseases, anti-inflammatory agents, and kinase inhibitors dominate the patent filings landscape.
Patent strategy insights
- The claims' breadth offers good protection for a family of compounds, but the existence of prior art in heterocyclic chemistry suggests that narrow, example-driven claims could face challenges.
- Future filings should emphasize specific therapeutic targets or compositions to strengthen patent position.
- Licensing or collaborations could be strategic, considering the crowded landscape.
Summary table of patent landscape elements
| Aspect |
Details |
| Patent family |
Extended patent protection, including Europe and the US |
| Related patents |
Overlap with heterocyclic compound patents, e.g., EP3456789 |
| Key competitors |
AstraZeneca, Novartis, Merck |
| Filing trends |
Increasing since 2010, focused on neurodegeneration and inflammation |
| Scope |
Chemical compounds, processes, and therapeutic uses |
Key Takeaways
- Patent ES2875432 secures rights on a versatile class of heterocyclic compounds with potential pharmaceutical applications.
- Its claims cover compounds, compositions, and synthesis methods, providing broad protection.
- The patent landscape for similar compounds in Spain is active, with overlapping patents by several major pharmaceutical companies.
- Ensuring claim specificity related to therapeutic indications could reinforce patent validity amid prior art.
- Strategic licensing, further patent filings, or focusing on unique synthesis routes are advisable for robust positioning.
FAQs
1. Can the scope of ES2875432 be challenged on grounds of prior art?
Yes. The broad chemical claims risk being vulnerable to prior art disclosures, especially in heterocyclic chemistry. Patent examiners will scrutinize novelty and inventive step based on existing chemical patents and publications.
2. Does the patent cover specific therapeutic uses?
While some claims relate to pharmaceutical compositions and methods of use, the primary focus appears on chemical compounds and synthesis. Use claims are often narrower and may require additional patent applications to strengthen protection.
3. How broad are the chemical claims in this patent?
They cover a family of heterocyclic compounds with variable substituents, making them quite broad but also potentially susceptible to validity challenges if prior art discloses similar structures.
4. What are the key considerations for filing related patents?
Focus on specific therapeutic indications, novel synthesis processes, or unique compound derivatives. Combining structural claims with method-of-use claims enhances overlap and coverage.
5. How does this patent impact competitors?
It potentially restricts others from manufacturing or using similar heterocyclic compounds for the covered indications within Spain and regional markets, pending validation and potential licensing opportunities.
References
[1] European Patent Office. (2023). Patent EP3456789. Retrieved from https://worldwide.espacenet.com/
[2] Spanish Patent and Trademark Office. (2022). Patent application reports.
Note: Continued review of patent specifics and legal status is recommended for in-depth strategy.
